WHO Drug Information, Vol. 21, No. 1, 2007                                                 Recommended INN: List 57



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 57
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9)], the following names are selected as Recommended International
Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not
imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–91) and Recommended (1–52) International Nonproprietary Names can be found in Cumulative List
No. 11, 2004 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 57
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies
par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion
d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la
substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–91) et recommandées (1–52) dans
la Liste récapitulative No. 11, 2004 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 57
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a
continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La
inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación
alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–91) y Recomendadas (1–52) se encuentran
reunidas en Cumulative List No. 11, 2004 (disponible sólo en CD-ROM).




                                                                                                                    53
Recommended INN: List 57                                                       WHO Drug Information, Vol. 21, No. 1, 2007




 Latin, English, French, Spanish:
 Recommended INN                          Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                          Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                          Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada




 abagovomabum*
 abagovomab                                      immunoglobulin G1, anti-idiotype anti-[anti-(Homo sapiens cancer
                                                 antigen 125, CA 125, MUC-16) Mus musculus monoclonal antibody
                                                 OC125] Mus musculus monoclonal antibody ACA125, clone 3D5
                                                 gamma1 heavy chain disulfide with clone 3D5 kappa light chain;
                                                 (223-223'':226-226'':228-228'') trisdisulfide dimer

 abagovomab                                      immunoglobuline G1, anti-idiotype anti-[anti-(Homo sapiens cancer
                                                 antigen 125, CA 125, MUC-16) anticorps monoclonal murin OC125]
                                                 anticorps monoclonal murin ACA125, chaîne lourde gamma1 du
                                                 clone 3D5 unie par un pont disulfure à la chaîne légère kappa du
                                                 clone 3D5; dimère (223-223'':226-226'':228-228'')-trisdisulfure

 abagovomab                                      inmunoglobulina G1, anti-idiotipo anti-[anti-(Homo sapiens cancer
                                                 antígeno 125, CA 125, MUC-16) anticuerpo monoclonal murino
                                                 OC125] anticuerpo monoclonal murino ACA125, cadena pesada
                                                 gamma1 del clon 3D5 unida por un puente disulfuro a la cadena
                                                 ligera kappa del clon 3D5; dímero (223-223'':226-226'':228-228'')-
                                                 trisdisulfuro

                                                  Heavy chain/Chaîne lourde/Cadena pesada
                                                  QVKLQESGAE LARPGASVKL SCKASGYTFT           NYWMQWVKQR   PGQGLDWIGA    50
                                                  IYPGDGNTRY THKFKGKATL TADKSSSTAY           MQLSSLASED   SGVYYCARGE   100
                                                  GNYAWFAYWG QGTTVTVSSA KTTPPSVYPL           APGSAAQTNS   MVTLGCLVKG   150
                                                  YFPEPVTVTW NSGSLSSGVH TFPAVLQSDL           YTLSSSVTVP   SSTWPSETVT   200
                                                  CNVAHPASST KVDKKIVPRD CGCKPCICTV           PEVSSVFIFP   PKPKDVLTIT   250
                                                  LTPKVTCVVV DISKDDPEVQ FSWFVDDVEV           HTAQTQPREE   QFNSTFRSVS   300
                                                  ELPIMHQDWL NGKEFKCRVN SAAFPAPIEK           TISKTKGRPK   APQVYTIPPP   350
                                                  KEQMAKDKVS LTCMITDFFP EDITVEWQWN           GQPAENYKNT   QPIMDTDGSY   400
                                                  FVYSKLNVQK SNWEAGNTFT CSVLHEGLHN           HHTEKSLSHS   PGK          443


                                                  Light chain/Chaîne légère/Cadena ligera
                                                  DIELTQSPAS LSASVGETVT ITCQASENIY           SYLAWHQQKQ   GKSPQLLVYN    50
                                                  AKTLAGGVSS RFSGSGSGTH FSLKIKSLQP           EDFGIYYCQH   HYGILPTFGG   100
                                                  GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA           SVVCFLNNFY   PKDINVKWKI   150
                                                  DGSERQNGVL NSWTDQDSKD STYSMSSTLT           LTKDEYERHN   SYTCEATHKT   200
                                                  STSPIVKSFN RNEC                                                      214


                                   123
 acidum iodofilticum (               I)
                  123                                              123
 iodofiltic acid ( I)                            (3RS)-15-[4-[       I]iodophenyl]3-methylpentadecanoic acid
                        123                                              123
 acide iodofiltique (         I)                 acide (3RS)-15-(4-[       I]iodophényl)-3-méthylpentadécanoïque
                   123                                                   123
 ácido iodofíltico (     I)                      ácido (3RS)-15-(4-[       I]iodofenil)-3-metilpentadecanoico
                                                           123
                                                 C22H35      IO2

                                                                                                      H CH3
                                                                                                                CO2H

                                                                                     and enantiomer
                                                  [123I]                             et énantiomère
                                                                                     y enantiómero


54
WHO Drug Information, Vol. 21, No. 1, 2007                                                  Recommended INN: List 57




 aclidinii bromidum
 aclidinium bromide                          (3R)-3-[(hydroxy)di(thiophen-2-yl)acetyloxy]-1-(3-phenoxypropyl)-
                                               5
                                             1λ -azabicyclo[2.2.2]octan-1-ylium bromide

 bromure d’aclidinium                        bromure de (3R)-3-[[hydroxybis(thiophén-2-yl)acétyl]oxy]-
                                             1-(3-phénoxypropyl)-1-azoniabicyclo[2.2.2]octane

 bromuro de aclidinio                        bromuro de (3R)-1-(3-fenoxipropil)-3-[(hidroxi)di(tiofen-2-il)acetiloxi]-
                                               5
                                             1λ -azabiciclo[2.2.2]octan-1-ilio

                                             C26H30BrNO4S2

                                                    S    O
                                                              H
                                                              O
                                                                     N+
                                                S        OH

                                                                    Br-          O




 afimoxifenum
 afimoxifene                                 4-(1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenylbut-1-enyl)phenol

 afimoxifène                                 4-[1-[4-[2-(diméthylamino)éthoxy]phényl]-2-phénylbut-1-ényl]phénol

 afimoxifeno                                 4-[1-[4-[2-(dimetilamino)etoxi]fenil]-2-fenilbut-1-enil]fenol

                                             C26H29NO2

                                                   H3C                O              CH3
                                                                                 N
                                                                                 CH3
                                                                                           and Z isomer
                                                                                           et l'isomère Z
                                                                                           y el isómero Z



                                                          OH



 afliberceptum*
 aflibercept                                 des-432-lysine-[human vascular endothelial growth factor receptor
                                             1-(103-204)-peptide (containing Ig-like C2-type 2 domain) fusion
                                             protein with human vascular endothelial growth factor receptor
                                             2-(206-308)-peptide (containing Ig-like C2-type 3 domain fragment)
                                             fusion protein with human immunoglobulin G1-(227 C-terminal
                                             residues)-peptide (Fc fragment)], (211-211':214-214')-bisdisulfide
                                             dimer

 aflibercept                                 (211-211':214-214')-bisdisulfure du dimère de la dès-432-lysine-
                                             [récepteur 1 humain du facteur de croissance endothélial vasculaire-
                                             (103-204)-peptide (contenant le domaine Ig-like C2-type 2) protéine
                                             de fusion avec le récepteur 2 humain du facteur de croissance
                                             endothélial vasculaire-(206-308)-peptide (contenant un fragment du
                                             domaine Ig-like C2-type 3) protéine de fusion avec
                                             l’immunoglobuline G1 humaine-(227 résidus C-terminaux)-peptide
                                             (fragment Fc)]




                                                                                                                         55
Recommended INN: List 57                                            WHO Drug Information, Vol. 21, No. 1, 2007


 aflibercept                   (211-211':214-214')-bisdisulfuro del dímero de la des-432-lisina-
                               [receptor 1 humano del factor de crecimiento endotelial vascular-
                               (103-204)-péptido (que contiene el dominio Ig-like C2-tipo 2)
                               proteína de fusión con el receptor 2 humano del factor de
                               crecimiento endotelial vascular-(206-308)-péptido (que contiene un
                               fragmento del dominio Ig-like C2-tipo 3) proteína de fusión con la
                               inmunoglobulina G1 humana-(227 restos C-terminales)-péptido
                               (fragmento Fc)]

                               C4318H6788N1164O1304S32

                               Monomer / Monomère / Monómero
                               SDTGRPFVEM YSEIPEIIHM TEGRELVIPC                   RVTSPNITVT      LKKFPLDTLI       50
                               PDGKRIIWDS RKGFIISNAT YKEIGLLTCE                   ATVNGHLYKT      NYLTHRQTNT       100
                               IIDVVLSPSH GIELSVGEKL VLNCTARTEL                   NVGIDFNWEY      PSSKHQHKKL       150
                               VNRDLKTQSG SEMKKFLSTL TIDGVTRSDQ                   GLYTCAASSG      LMTKKNSTFV       200
                               RVHEKDKTHT CPPCPAPELL GGPSVFLFPP                   KPKDTLMISR      TPEVTCVVVD       250
                               VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ                   YNSTYRVVSV      LTVLHQDWLN       300
                               GKEYKCKVSN KALPAPIEKT ISKAKGQPRE                   PQVYTLPPSR      DELTKNQVSL       350
                               TCLVKGFYPS DIAVEWESNG QPENNYKTTP                   PVLDSDGSFF      LYSKLTVDKS       400
                               RWQQGNVFSC SVMHEALHNH YTQKSLSLSP                   G                                431


                               Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                               30-79     30'-79' 124-185 124'-185' 211-211'
                               214-214' 246-306 246'-306' 352-410 352'-410'




 aleglitazarum
 aleglitazar                   (2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-
                               1-benzothiophen-7-yl}propanoic acid

 aléglitazar                   acide (2S)-2-méthoxy-3-[4-[2-(5-méthyl-2-phényl-1,3-oxazol-
                               4-yl)éthoxy]-1-benzothiophén-7-yl]propanoïque

 aleglitazar                   ácido (2S)-3-{4-[2-(2-fenil-1,3-oxazol-5-metil-4-il)etoxi]-
                               1-benzotiofen-7-il}-2-metoxipropanoico

                               C24H23NO5S

                                                                   O               CH3
                                                N
                                                                                  O H

                                                 O        CH3                           CO2H
                                                                              S



 alferminogenum tadenovecum*
 alferminogene tadenovec       recombinant human adenovirus 5 (replication-deficient, E1-deleted)
                               containing a human fibroblast growth factor-4 cDNA sequence driven
                               by a cytomegalovirus promoter

 alferminogène tadénovec       adénovirus 5 humain recombinant (réplication-déficient, région E1-
                               supprimée) contenant la séquence ADN-copie du facteur 4 de
                               croissance du fibroblaste humain sous contrôle d’un promoteur de
                               cytomégalovirus

 alferminogén tadenovec        adenovirus 5 humano recombinante (replicación-deficiente, con
                               delección E1) que contiene la secuencia DNA-copia del factor-4 de
                               crecimiento de fibroblastos humanos controlado por un promotor de
                               citomegalovirus




56
WHO Drug Information, Vol. 21, No. 1, 2007                                                  Recommended INN: List 57


 apilimodum
 apilimod                                    1-[(3-methylphenyl)methylidene]-2-{6-(morpholin-4-yl)-2-[2-(pyridin-
                                             2-yl)ethoxy]pyrimidin-4-yl}hydrazine

 apilimod                                    1-(3-méthylbenzylidène)-2-[6-(morpholin-4-yl)-2-[2-(pyridin-2-yl)=
                                             éthoxy]pyrimidin-4-yl]diazane

 apilimod                                    1-(3-metilbencilideno)-2-[6-(morfolin-4-il)-2-[2-(piridin-2-il)etoxi]=
                                             pirimidin-4-il]diazano

                                             C23H26N6O2

                                                                             H
                                                N               O       N    N
                                                                                  N
                                                                    N

                                                                        N
                                                                                      CH3
                                                                        O



 apricitabinum
 apricitabine                                4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-
                                             2(1H)-one

 apricitabine                                (-)-4-amino-1-[(2R,4R)-2-(hydroxyméthyl)-1,3-oxathiolan-4-yl]=
                                             pyrimidin-2(1H)-one

 apricitabina                                (-)-4-amino-1-[(2R,4R)-2-(hidroximetil)-1,3-oxatiolan-4-il]pirimidin-
                                             2(1H)-ona

                                             C8H11N3O3S

                                                                O       N   NH2

                                                            S       N
                                             HO
                                                    H               H
                                                        O



 artemisonum
 artemisone                                  4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyldecahydro-
                                             12H-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-yl]=
                                             thiomorpholine-1,1-dione

 artémisone                                  1,1-dioxyde de 4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-
                                             triméthyldécahydro-3,12-époxypyrano[4,3-j]-1,2-benzodioxépin-
                                             10-yl]thiomorpholine

 artemisona                                  1,1-dióxido de 4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-
                                             trimetildecahidro-3,12-epoxipirano[4,3-j]-1,2-benzodioxepin-10-il]=
                                             tiomorfolina




                                                                                                                      57
Recommended INN: List 57                                         WHO Drug Information, Vol. 21, No. 1, 2007


                           C19H31NO6S

                                                                     O
                                              CH3                  S O
                                            H   H
                                                          N
                              H                           H
                                                      O
                           H3C
                                   H                  H
                                            O     O


                                            O     CH3



 ataciceptum*
 atacicept                 [86-serine,101-glutamic acid,196-serine,197-serine,222-aspartic
                           acid,224-leucine][human tumor necrosis factor receptor superfamily
                           member 13B-(30-110)-peptide (TACI fragment containing TNFR-Cys
                           1 and TNFR-Cys 2) fusion protein with human immunogobulin G1-
                           (232 C-terminal residues)-peptide (γ1-chain Fc fragment), (92-92':95-
                           95')-bisdisulfide dimer

 atacicept                 (92-92':95-95')-bisdisulfure du dimère de la [86-sérine,101-acide
                           glutamique,196-sérine,197-sérine,222-acide aspartique,
                           224-leucine]-protéine de fusion du membre 13B humain de la
                           superfamille des récepteurs du facteur de nécrose tumorale-
                           (30-110)-peptide (portion du TACI incluant les deux régions riches
                           en cystéine) avec l’immunoglobuline G1 humaine-(232 résidus
                           C-terminaux)-peptide (fragment Fc de la chaîne γ1)

 atacicept                 92-92':95-95')-bisdisulfuro del dímero de la [86-serina,101-ácido
                           glutámico,196-serina,197-serina,222-ácido aspártico,224-leucina]-
                           proteína de fusión del miembro 13B humano de la superfamilia de
                           receptores del factor de necrosis tumoral-(30-110)-péptido (porción
                           del TACI que incluye las dos regiones ricas en cisteína) con la
                           inmunoglobulina G1 humana-(232 restos C-terminales)-péptido
                           (fragmento Fc de la cadena γ1)

                           C3104H4788N856O950S44

                           Monomer / Monomère / Monómero
                           AMRSCPEEQY WDPLLGTCMS CKTICNHQSQ                             RTCAAFCRSL   SCRKEQGKFY      50
                           DHLLRDCISC ASICGQHPKQ CAYFCENKLR                             SEPKSSDKTH   TCPPCPAPEA      100
                           EGAPSVFLFP PKPKDTLMIS RTPEVTCVVV                             DVSHEDPEVK   FNWYVDGVEV      150
                           HNAKTKPREE QYNSTYRVVS VLTVLHQDWL                             NGKEYKCKVS   NKALPSSIEK      200
                           TISKAKGQPR EPQVYTLPPS RDELTKNQVS                             LTCLVKGFYP   SDIAVEWESN      250
                           GQPENNYKTT PPVLDSDGSF FLYSKLTVDK                             SRWQQGNVFS   CSVMHEALHN      300
                           HYTQKSLSLS PGK                                                                            313

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           5-18    5'-18' 21-33 21'-33' 25-37 25'-37' 42-57      42'-57' 60-71
                           60'-71' 64-75 64'-75' 92-92' 95-95' 127-187 127'-187' 233-291 233'-291'




 azilsartanum
 azilsartan                2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-
                           1,1'-biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid

 azilsartan                acide 2-éthoxy-1-[[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)=
                           biphényl-4-yl]méthyl]-1H-benzimidazole-7-carboxylique

 azilsartán                ácido 2-etoxi-1-{[2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-
                           4-il]metil}-1H-bencimidazol-7-carboxílico



58
WHO Drug Information, Vol. 21, No. 1, 2007                                                                               Recommended INN: List 57


                                             C25H20N4O5

                                                                                       O
                                                        CO2H
                                                                                                 O
                                                                                      HN           N
                                                              N

                                                         N          O

                                                                         CH3




 bavituximabum*
 bavituximab                                 immunoglobulin G1, anti-(phosphatidylserine) chimeric monoclonal
                                             ch3G4; gamma1 heavy chain (Mus musculus VH-Homo sapiens
                                             IGHG1) (223-214')-disulfide with kappa light chain (Mus musculus
                                             V-KAPPA-Homo sapiens IGKC); (229-229'':232-232'')-bisdisulfide
                                             dimer

 bavituximab                                 immunoglobuline G1, anti-(phosphatidylsérine) anticorps monoclonal
                                             chimérique ch3G4; chaîne lourde gamma1 (Mus musculus VH-
                                             Homo sapiens IGHG1) (223-214')-disulfure avec la chaîne légère
                                             kappa (Mus musculus V-KAPPA-Homo sapiens IGKC); dimère
                                             (229-229'':232-232'')-bisdisulfure

 bavituximab                                 inmunoglobulina G1, anti-(fosfatidilserina) anticuerpo monoclonal
                                             quimérico ch3G4; cadena pesada gamma1 (Mus musculus VH-
                                             Homo sapiens IGHG1) (223-214')-disulfuro con la cadena ligera
                                             kappa (Mus musculus V-KAPPA-Homo sapiens IGKC), dímero
                                             (229-229'':232-232'')-bisdisulfuro

                                             C6446H9946N1702O2042S42

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLQQSGPE LEKPGASVKL SCKASGYSFT                                        GYNMNWVKQS        HGKSLEWIGH   50
                                             IDPYYGDTSY NQKFRGKATL TVDKSSSTAY                                        MQLKSLTSED        SAVYYCVKGG   100
                                             YYGHWYFDVW GAGTTVTVSS ASTKGPSVFP                                        LAPSSKSTSG        GTAALGCLVK   150
                                             DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                                        GLYSLSSVVT        VPSSSLGTQT   200
                                             YICNVNHKPS NTKVDKKVEP KSCDKTHTCP                                        PCPAPELLGG        PSVFLFPPKP   250
                                             KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                                        YVDGVEVHNA        KTKPREEQYN   300
                                             STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                                        LPAPIEKTIS        KAKGQPREPQ   350
                                             VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI                                        AVEWESNGQP        ENNYKTTPPV   400
                                             LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                                        MHEALHNHYT        QKSLSLSPGK   450

                                             k Chain / Chaîne k / Cadena k
                                             DIQMTQSPSS LSASLGERVS                           LTCRASQDIG              SSLNWLQQGP        DGTIKRLIYA   50'
                                             TSSLDSGVPK RFSGSRSGSD                           YSLTISSLES              EDFVDYYCLQ        YVSSPPTFGA   100'
                                             GTKLELKRAD AAPSVFIFPP                           SDEQLKSGTA              SVVCLLNNFY        PREAKVQWKV   150'
                                             DNALQSGNSQ ESVTEQDSKD                           STYSLSSTLT              LSKADYEKHK        VYACEVTHQG   200'
                                             LSSPVTKSFN RGEC                                                                                          214'

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             22-96    22''-96''    23'-88'   23'''-88''' 134'-194' 134'''-194''' 147-203 147''-203''
                                             214'-223 214'''-223'' 229-229'' 232-232'' 264-324 264''-324'' 370-428 370''-428''




                                                                                                                                                             59
Recommended INN: List 57                                 WHO Drug Information, Vol. 21, No. 1, 2007


 bedoradrinum
 bedoradrine                    2-{[(7S)-7-({(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]=
                                ethyl}amino)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}-
                                N,N-dimethylacetamide

 bédoradrine                    (-)-2-[[(7S)-7-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyéthyl)=
                                phényl]éthyl]amino]-5,6,7,8-tétrahydronaphtalén-2-yl]oxy]-
                                N,N-diméthylacétamide

 bedoradrina                    (-)-2-{[(7S)-7-({(2R)-2-hidroxi-2-[4-hidroxi-3-(2-hidroxietil)fenil]=
                                etil}amino)-5,6,7,8-tetrahidronaftalen-2-il]oxi}-N,N-dimetilacetamida

                                C24H32N2O5

                                             H OH                           O
                                                    H
                                                    N                 O             CH3
                                                                                N
                                                    H
                                                                                CH3
                                HO
                                              OH




 beperminogenum perplasmidum*
 beperminogene perplasmid       plasmid DNA containing human hepatocyte growth factor cDNA
                                sequence driven by a cytomegalovirus promoter

 béperminogène perplasmide      ADN plasmidique contenant la séquence ADN-copie du facteur de
                                croissance de l’hépatocyte humain sous contrôle d’un promoteur de
                                cytomégalovirus

 beperminogén perplásmido       DNA de plásmido que contiene la secuencia DNA-copia del factor
                                de crecimiento del hepatocito humano controlado por un promotor
                                de citomegalovirus




 beroctocogum alfa*
 beroctocog alfa                human blood-coagulation factor VIII-(1-740)-peptide complex with
                                human blood-coagulation factor VIII-(1649-2332)-peptide

 béroctocog alfa                combinaison du facteur VIII de coagulation humain-(1-740)-peptide
                                (chaîne lourde du facteur VIIIa, isoforme de 92 kDa) avec le facteur
                                VIII de coagulation humain-(1649-2332)-peptide (chaîne légère du
                                facteur VIIIa)

 beroctocog alfa                combinación del factor VIII de coagulación humano-(1-740)-péptido
                                (cadena pesada del factor VIIIa, isoforma de 92 kDa) con el factor
                                VIII de coagulación humano-(1649-2332)-péptido (cadena ligèra del
                                factor VIIIa)




60
WHO Drug Information, Vol. 21, No. 1, 2007                                                             Recommended INN: List 57


                                             C3821H5813N1003O1139S35 + C3553H5400N956O1032S35

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             ATRRYYLGAV ELSWDYMQSD LGELPVDARF                       PPRVPKSFPF            NTSVVYKKTL   50
                                             FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV                       YDTVVITLKN            MASHPVSLHA   100
                                             VGVSYWKASE GAEYDDQTSQ REKEDDKVFP                       GGSHTYVWQV            LKENGPMASD   150
                                             PLCLTYSYLS HVDLVKDLNS GLIGALLVCR                       EGSLAKEKTQ            TLHKFILLFA   200
                                             VFDEGKSWHS ETKNSLMQDR DAASARAWPK                       MHTVNGYVNR            SLPGLIGCHR   250
                                             KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN                       HRQASLEISP            ITFLTAQTLL   300
                                             MDLGQFLLFC HISSHQHDGM EAYVKVDSCP                       EEPQLRMKNN            EEAEDYDDDL   350
                                             TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK                       TWVHYIAAEE            EDWDYAPLVL   400
                                             APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA                       YTDETFKTRE            AIQHESGILG   450
                                             PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI                       TDVRPLYSRR            LPKGVKHLKD   500
                                             FPILPGEIFK YKWTVTVEDG PTKSDPRCLT                       RYYSSFVNME            RDLASGLIGP   550
                                             LLICYKESVD QRGNQIMSDK RNVILFSVFD                       ENRSWYLTEN            IQRFLPNPAG   600
                                             VQLEDPEFQA SNIMHSINGY VFDSLQLSVC                       LHEVAYWYIL            SIGAQTDFLS   650
                                             VFFSGYTFKH KMVYEDTLTL FPFSGETVFM                       SMENPGLWIL            GCHNSDFRNR   700
                                             GMTALLKVSS CDKNTGDYYE DSYEDISAYL                       LSKNNAIEPR            S              741

                                             Light chain / Chaîne légère / Cadena ligera
                                                                                                                                 EI 1650
                                             TRTTLQSDQE        EIDYDDTISV         EMKKEDFDIY        DEDENQSPRS            FQKKTRHYFI 1700
                                             AAVERLWDYG        MSSSPHVLRN         RAQSGSVPQF        KKVVFQEFTD            GSFTQPLYRG 1750
                                             ELNEHLGLLG        PYIRAEVEDN         IMVTFRNQAS        RPYSFYSSLI            SYEEDQRQGA 1800
                                             EPRKNFVKPN        ETKTYFWKVQ         HHMAPTKDEF        DCKAWAYFSD            VDLEKDVHSG 1850
                                             LIGPLLVCHT        NTLNPAHGRQ         VTVQEFALFF        TIFDETKSWY            FTENMERNCR 1900
                                             APCNIQMEDP        TFKENYRFHA         INGYIMDTLP        GLVMAQDQRI            RWYLLSMGSN 1950
                                             ENIHSIHFSG        HVFTVRKKEE         YKMALYNLYP        GVFETVEMLP            SKAGIWRVEC 2000
                                             LIGEHLHAGM        STLFLVYSNK         CQTPLGMASG        HIRDFQITAS            GQYGQWAPKL 2050
                                             ARLHYSGSIN        AWSTKEPFSW         IKVDLLAPMI        IHGIKTQGAR            QKFSSLYISQ 2100
                                             FIIMYSLDGK        KWQTYRGNST         GTLMVFFGNV        DSSGIKHNIF            NPPIIARYIR 2150
                                             LHPTHYSIRS        TLRMELMGCD         LNSCSMPLGM        ESKAISDAQI            TASSYFTNMF 2200
                                             ATWSPSKARL        HLQGRSNAWR         PQVNNPKEWL        QVDFQKTMKV            TGVTTQGVKS 2250
                                             LLTSMYVKEF        LISSSQDGHQ         WTLFFQNGKV        KVFQGNQDSF            TPVVNSLDPP 2300
                                             LLTRYLRIHP        QSWVHQIALR         MEVLGCEAQD        LY                                   2332

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             153-179 528-554 1899-1903 2021-2169 2174-2326

                                             Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
                                             Asn-41 Asn-239 Asn-582 Asn-1810 Asn-2118

                                             Modifications / Modificaciones
                                             Y = 4-O-sulfotyrosyl




 bremelanotidum
 bremelanotide                               2,7-anhydro(N-acetyl-L-2-aminohexanoyl-L-aspartyl-L-histidyl-
                                             D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysine)

 brémelanotide                               N-acétyl-L-2-aminohexanoyl-L-α-aspartyl-L-histidyl-D-phénylalanyl-
                                             L-arginyl-L-tryptophyl-L-lysine-(2→7)-lactame

 bremelanotida                               N-acetil-L-2-aminohexanoil-L-α-aspartil-L-histidil-D-fenilalanil-
                                             L-arginil-L-triptofil-L-lisina-(2→7)-lactama

                                             C50H68N14O10

                                                                       O
                                                    H3C                                                  NH

                                                     O         H             H                                                H

                                             H3 C         N           N            L-His D-Phe L-Arg         L-Trp N           CO2H
                                                          H           H                                               H
                                                                 O            O




                                                                                                                                               61
Recommended INN: List 57                                        WHO Drug Information, Vol. 21, No. 1, 2007


 bucelipasum alfa*
 bucelipase alfa           human bile-salt-activated lipase (cholesterol esterase, EC 3.1.1.13),
                           glycoform alfa (recombinant hBSSL)

 bucélipase alfa           lipase activée par les sels biliaires humaine (cholestérol estérase,
                           EC 3.1.1.13), glycoforme alpha (recombinante hBSSL)

 bucelipasa alfa           lipasa humana activada por las sales biliares (colesterol esterasa,
                           EC 3.1.1.13), glicoforma alfa (recombinante hBSSL)

                           C3434H5258N894O1041S17

                           AKLGAVYTEG         GFVEGVNKKL         GLLGDSVDIF        KGIPFAAPTK           ALENPQPHPG   50
                           WQGTLKAKNF         KKRCLQATIT         QDSTYGDEDC        LYLNIWVPQG           RKQVSRDLPV   100
                           MIWIYGGAFL         MGSGHGANFL         NNYLYDGEEI        ATRGNVIVVT           FNYRVGPLGF   150
                           LSTGDANLPG         NYGLRDQHMA         IAWVKRNIAA        FGGDPNNITL           FGESAGGASV   200
                           SLQTLSPYNK         GLIRRAISQS         GVALSPWVIQ        KNPLFWAKKV           AEKVGCPVGD   250
                           AARMAQCLKV         TDPRALTLAY         KVPLAGLEYP        MLHYVGFVPV           IDGDFIPADP   300
                           INLYANAADI         DYIAGTNNMD         GHIFASIDMP        AINKGNKKVT           EEDFYKLVSE   350
                           FTITKGLRGA         KTTFDVYTES         WAQDPSQENK        KKTVVDFETD           VLFLVPTEIA   400
                           LAQHRANAKS         AKTYAYLFSH         PSRMPVYPKW        VGADHADDIQ           YVFGKPFATP   450
                           TGYRPQDRTV         SKAMIAYWTN         FAKTGDPNMG        DSAVPTHWEP           YTTENSGYLE   500
                           ITKKMGSSSM         KRSLRTNFLR         YWTLTYLALP        TVTDQEATPV           PPTGDSEATP   550
                           VPPTGDSETA         PVPPTGDSGA         PPVPPTGDSG        APPVPPTGDS           GAPPVPPTGD   600
                           SGAPPVPPTG         DSGAPPVPPT         GDSGAPPVPP        TGDSGAPPVP           PTGDAGPPPV   650
                           PPTGDSGAPP         VPPTGDSGAP         PVTPTGDSET        APVPPTGDSG           APPVPPTGDS   700
                           EAAPVPPTDD         SKEAQMPAVI         RF                                                    722

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           64-80 246-257

                           Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
                           Asn-187 Thr-538 Thr-549 Thr-559 Thr-576 Thr-587
                           Thr-598 Thr-609 Thr-620 Thr-631 Thr-642




 camobucolum
 camobucol                 4-{4-[(2-{[3,5-di(tert-butyl)-4-hydroxyphenyl]sulfanyl}propan-2-yl)=
                           sulfanyl]-2,6-di(tert-butyl)phenoxy}acetic acid

 camobucol                 acide 4-{4-[(2-{[3,5-di(tert-butyl)-4-hydroxyphényl]sulfanyl}propan-
                           2-yl)sulfanyl]-2,6-di(tert-butyl)phénoxy}acétique

 camobucol                 ácido 4-{4-[(2-{[3,5-di(terc-butil)4-hidroxifenil]sulfanil}propan-2-il)=
                           sulfanil]-2,6-di(terc-butil)fenoxi}acético

                           C33H50O4S2

                                             CH3                H3C
                                   H3 C                                 CH3
                                               CH3          H3 C
                                 HO                                          O         CO2H
                                                  H3C     CH3
                           H3C                                                    CH3
                                                   S        S
                             H3C      CH3                              H3C       CH3



 capadenosonum
 capadenoson               2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-
                           4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile

 capadénoson               2-amino-6-[[[2-(4-chlorophényl)-1,3-thiazol-4-yl]méthyl]sulfanyl]-
                           4-[4-(2-hydroxyéthoxy)phényl]pyridine-3,5-dicarbonitrile

 capadenosón               2-amino-6-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-
                           4-[4-(2-hidroxietoxi)fenil]piridina-3,5-dicarbonitrilo


62
WHO Drug Information, Vol. 21, No. 1, 2007                                                         Recommended INN: List 57


                                             C25H18ClN5O2S2

                                                                                     NH2
                                                                                              CN
                                                                                 N

                                                               N
                                                                           S
                                             Cl
                                                                                     CN                           OH
                                                               S                                        O



 catramilastum
 catramilast                                 1-{(2S)-2-[3-(cyclopropylmethoxy)-4-methoxyphenyl]propyl}-
                                             1,3-dihydro-2H-imidazol-2-one

 catramilast                                 1-[(2S)-2-[3-(cyclopropylméthoxy)-4-méthoxyphényl]propyl]-
                                             1,3-dihydro-2H-imidazol-2-one

 catramilast                                 1-{(2S)-2-[3-(ciclopropilmetoxi)-4-metoxifenil]propil}-1,3-dihidro-
                                             2H-imidazol-2-ona

                                             C17H22N2O3

                                                   H3CO
                                                                                     O

                                                       O                     N
                                                                                         NH
                                                                   H   CH3




 cediranibum
 cediranib                                   4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-
                                             1-yl)propoxy]quinazoline

 cédiranib                                   4-[(4-fluoro-2-méthyl-1H-indol-5-yl)oxy]-6-méthoxy-7-[3-(pyrrolidin-
                                             1-yl)propoxy]quinazoline

 cediranib                                   4-[(4-fluoro-2-metil-1H-indol-5-il)oxi]-6-metoxi-7-[3-(pirrolidin-1-il)=
                                             propoxi]quinazolina

                                             C25H27FN4O3

                                                                                                    H
                                                                                                    N
                                                                       N         N
                                                                                                            CH3
                                                                                     O
                                                                                              F
                                                  N            O
                                                                       OCH3



 denibulinum
 denibulin                                   methyl [5-({4-[(2S)-2-aminopropanamido]phenyl}sulfanyl)-
                                             1H-benzimidazol-2-yl]carbamate

 dénibuline                                  [5-[[4-[[(2S)-2-aminopropanamido]phenyl]sulfanyl]-1H-benzimidazol-
                                             2-yl]carbamate de méthyle

 denibulina                                  [5-({4-[(2S)-2-aminopropanamido]fenil}sulfanil)-1H-bencimidazol-
                                             2-il]carbamato de metilo


                                                                                                                         63
Recommended INN: List 57                                      WHO Drug Information, Vol. 21, No. 1, 2007


                           C18H19N5O3S

                                H   NH2                                        O
                                          H                             H
                                          N                             N           O
                           H3C
                                                                               NH       CH3
                                    O
                                                          S             N




 dexelvucitabinum
 dexelvucitabine           4-amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-
                           2-yl]pyrimidin-2(1H)-one

 dexelvucitabine           (+)-4-amino-5-fluoro-1-[(2R,5S)-5-(hydroxyméthyl)-2,5-dihydrofuran-
                           2-yl]pyrimidin-2(1H)-one

 dexelvucitabina           (+)-4-amino-5-fluoro-1-[(2R,5S)-5-(hidroximetil)-2,5-dihidrofuran-
                           2-il]pirimidin-2(1H)-ona

                           C9H10FN3O3

                                              O       N       NH2

                                        O         N
                           HO                                 F




 efungumabum*
 efungumab                 immunoglobulin scFv fragment, anti-(heat shock protein 90 homolog
                           from Candida albicans (yeast)), methionylalanyl-[human monoclonal
                           HSP90mab VH domain (120 residues)]-tris[(tetraglycyl)seryl]-[human
                           monoclonal HSP90mab V-KAPPA domain (107 residues)]-[arginyl-
                           trialanyl-leucyl-glutamyl]-hexahistidine

 éfungumab                 immunoglobuline fragment scFv, anti-(homologue de la protéine de
                           choc thermique 90 de Candida albicans (levure)), methionylalanyl-
                           [domaine VH (120 residus) de l’anticorps monoclonal humain
                           HSP90mab]-tris[(tetraglycyl)seryl]-[domaine V-KAPPA (107 residus)
                           de l’anticorps monoclonal humain HSP90mab]-[arginyl-trialanyl-
                           leucyl-glutamyl]-hexahistidine

 efungumab                 inmunoglobulina fragmento scFv, anti-(homólogo de la proteína de
                           choc térmico 90 de Candida albicans ), metionilalanil-[dominio VH
                           (120 restos) del anticuerpo monoclonal humano HSP90mab]-
                           tris[(tetraglicil)seril]-[dominio V-KAPPA (107 restos) del anticuerpo
                           monoclonal humano HSP90mab]-[arginil-trialanil-leucil-glutamil]-
                           hexahistidina


                            MAEVQLVES         GAEVKKPGES          LRISCKGSGC   IISSYWISWV     RQMPGKGLEW
                           MGKIDPGDSY         INYSPSFQGH          VTISADKSIN   TAYLQWNSLK     ASDTAMYYCA
                           RGGRDFGDSF         DYWGQGTLVT          VSSGGGGSGG   GGSGGGGSDV     VMTQSPSFLS
                           AFVGDRITIT         CRASSGISRY          LAWYQQAPGK   APKLLIYAAS     TLQTGVPSRF
                           SGSGSGTEFT         LTINSLQPED          FATYYCQHLN   SYPLTFGGGT     KVDIKRAAA
                           LEhhhhhh




64
WHO Drug Information, Vol. 21, No. 1, 2007                                                              Recommended INN: List 57


 elocalcitolum
 elocalcitol                                 (1S,3R,5Z,7E,23E)-1-fluoro-26,27-dihomo-9,10-secocholesta-
                                             5,7,10(19),16,23-pentaene-3,25-diol

 élocalcitol                                 (1R,5S)-3-[(1Z)-2-[(3aS,4E,7aS)-1-[(1S,3E)-5-éthyl-5-hydroxy-
                                             1-méthylhept-3-ényl]-7a-méthyl-3,3a,5,6,7,7a-hexahydro-4H-indén-
                                             4-ylidène]éthylidène]-5-fluoro-4-méthylidènecyclohexanol

 elocalcitol                                 (1S,3R,5Z,7E,23E)-1-fluoro-26,27-dihomo-9,10-secocolesta-
                                             5,7,10(19),16,23-pentaeno-3,25-diol

                                             C29H43FO2

                                                               H3C H
                                                                                           CH3
                                                               CH3


                                                                                      OH
                                                                                    CH3
                                                               H


                                                               CH2

                                             HO                    F
                                                  H            H



 elsibucolum
 elsibucol                                   4-{4-[(2-{[3,5-di-tert-butyl-4-hydroxyphenyl]sulfanyl}propan-2-yl)=
                                             sulfanyl]-2,6-di-tert-butylphenoxy}butanoic acid

 elsibucol                                   acide 4-[4-[[1-[[3,5-bis(1,1-diméthyléthyl)-4-hydroxyphényl]sulfanyl]-
                                             1-méthyléthyl]sulfanyl]-2,6-bis(1,1-diméthyléthyl)phénoxy]butanoïque

 elsibucol                                   ácido 4-{4-[(2-{[3,5-di-terc-butil-4-hidroxifenil]sulfanil}propan-2-il)=
                                             sulfanil]-2,6-di-terc-butilfenoxi}butanoico

                                             C35H54O4S2

                                                               CH3                H3C
                                                      H3C                               CH3
                                                                   CH3        H3C
                                                    HO                                        O            CO2H
                                                                       H3C   CH3
                                             H3 C                                                 CH3
                                                                       S      S
                                               H3C       CH3                            H3C       CH3



 epoetinum theta
 epoetin theta                               human erythropoietin-(1-165)-peptide, glycoform θ

 époétine thêta                              érythropoïétine humaine-(1-165)-peptide, glycoforme θ

 epoetina zeta                               eritropoyetina humana-péptido-(1-165), glicoforma θ

                                             C809H1301N229O240S5




                                                                                                                              65
Recommended INN: List 57                                      WHO Drug Information, Vol. 21, No. 1, 2007


 ferroquinum
 ferroquine                N'-(7-chloroquinolin-4-yl)-N,N-dimethyl-C,C'-(ferrocene-1,2-diyl)=
                           dimethanamine

 ferroquine                N'-(7-chloroquinoléin-4-yl)-N,N-diméthyl-C,C'-(férrocène-1,2-diyl)=
                           diméthanamine

 ferroquina                N'-(7-cloroquinolin-4-il)-N,N-dimetil-C,C'-(ferroceno-1,2-diil)=
                           dimetanamina

                           C23H24ClFeN3

                           Cl             N




                                        HN

                                                              CH3

                                        Fe                    N
                                                                  CH3




 fluticasonum furoas
 fluticasone furoate       6α,9-difluoro-17{[(fluoromethyl)sulfanyl]carbonyl}-11β-hydroxy-
                           16α-methyl-3-oxoandrosta-1,4-dien-17α-yl furan-2-carboxylate

 furoate de fluticasone    furane-2-carboxylate de 6α,9-difluoro-17-[[(fluorométhyl)sulfanyl]=
                           carbonyl]-11β-hydroxy-16α-méthyl-3-oxoandrosta-1,4-dién-17α-yle

 furoato de fluticasona    furano-2-carboxilato de 6α,9-difluoro-17-[[(fluorometil)sulfanil]=
                           carbonil]-11β-hidroxi-16α-metil-3-oxoandrosta-1,4-dien-17α-ilo

                           C27H29F3O6S

                                                                       F
                                                          O           O
                                                                  S
                                          H           CH3
                                   HO                          O
                                    CH3           H             CH3 O
                                                              H
                                          F           H
                           O
                                      H       F



 fosalvudinum tidoxilum
 fosalvudine tidoxil       (2RS)-2-(decyloxy)-3-[(dodecyl)sulfanyl]propyl [(2R,3S,5R)-3-fluoro-
                           5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-
                           2-yl]methyl hydrogen phosphate

 fosalvudine tidoxil       hydrogénophosphate de (2RS)-2-(décyloxy)-3-(dodécylsulfanyl)=
                           propyle et de [(2R,3S,5R)-3-fluoro-5-(5-méthyl-2,4-dioxo-
                           3,4-dihydropyrimidin-1(2H)-yl)tétrahydrofuran-2-yl]méthyle

 fosalvudina tidoxilo      hidrógenofosfato de (2RS)-2-(deciloxi)-3-[(dodecil)sulfanil]propilo y
                           [(2R,3S,5R)-3-fluoro-5-(5-metil-2,4-dioxo-3,4-dihidropirimidin-
                           1(2H)-il)tetrahidrofuran-2-il]metilo



66
WHO Drug Information, Vol. 21, No. 1, 2007                                                               Recommended INN: List 57


                                             C35H64FN2O8PS

                                                                     and epimer at C*
                                                                     et l'épimère en C*                                         H
                                                                                                                        O       N   O
                                                    CH3              y el epímero al C*          O OH
                                                                                                     P              O       N
                                                                               S       *        O        O                          CH3
                                             H3C                                    O H
                                                                                                                F




 gamithromycinum
 gamithromycin                               (2R,3S,4R,5S,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-
                                             3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-
                                             trihydroxy-3,5,8,10,12,14-hexamethyl-7-propyl-11-{[3,4,6-trideoxy-
                                             3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy}-1-oxa-
                                             7-azacylopentadecan-15-one

 gamithromycin                               (2R,3S,4R,5S,8R,10R,11R,12S,13S,14R)-13-[(2,6-didésoxy-
                                             3-C-méthyl-3-O-méthyl-α-L-ribo-hexopyranosyl)oxy]-2-éthyl-3,4,10-
                                             trihydroxy-3,5,8,10,12,14-hexaméthyl-7-propyl-11-[[3,4,6-tridésoxy-
                                             3-(diméthylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-
                                             7-azacyclopentadécan-15-one

 gamitromicina                               (2R,3S,4R,5S,8R,10R,11R,12S,13S,14R)-13-[(2,6-didesoxi-
                                             3-C-metil-3-O-metil-α-L-ribo-hexopiranosil)oxi]-2-etil-3,4,10-trihidroxi-
                                             3,5,8,10,12,14-hexametil-7-propil-11-{[3,4,6-tridesoxi-
                                             3-(dimetilamino)-β-D-xylo-hexopiranosil]oxi}-1-oxa-
                                             7-azaciclopentadecan-15-ona

                                             C40H76N2O12

                                                                                               CH3

                                                                              H3C      N             CH3
                                                                               H                      H
                                                                            H3 C           H          OH
                                                   CH3                    HO           HO                 CH3
                                                         O O                            CH3               H
                                             H3C       CH3                                O
                                                   N                         H          H                     CH3
                                                                            O O
                                                                HO
                                                                                                     O
                                                                      CH3          H
                                                           OH         OCH3             H       CH3


                                                                      CH3



 ilepatrilum
 ilepatril                                   (4S,7S,12bR)-7-[(2S)-2-(acetylsulfanyl)-3-methylbutanamido]-6-oxo-
                                             1,2,3,4,6,7,8,12b-octahydropyrido[2,1-a][2]benzazepine-4-carboxylic
                                             acid

 ilépatril                                   acide (4S,7S,12bR)-7-[[(2S)-2-(acétylsulfanyl)-3-méthylbutanoyl]=
                                             amino]-6-oxo-1,2,3,4,6,7,8,12b-octahydropyrido[2,1-a][2]=
                                             benzazépine-4-carboxylique

 ilepatrilo                                  ácido (4S,7S,12bR)-7-{[(2S)-2-(acetilsulfanil)-3-metilbutanoil]amino}-
                                             6-oxo-1,2,3,4,6,7,8,12b-octahidropirido[2,1-a][2]benzazepina-
                                             4-carboxílico



                                                                                                                                          67
Recommended INN: List 57                                          WHO Drug Information, Vol. 21, No. 1, 2007


                           C22H28N2O5S

                                         CH3
                                 O
                                     H   S                   O H
                                                 H H                  CO2H
                           H3C                   N
                                                              N
                                 CH3         O

                                                              H




 imisopasemum manganum
 imisopasem manganese      (PBPY-7-11-2344'3')-dichloro[(4aR,13aR,17aR,21aR)-
                           1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-
                           icosahydro-7,11-(azeno)dibenzo[b,h][1,4,7,10]=
                                                      4 5  13  18 21  22
                           tetraazacycloheptadecine-κ N ,N ,N ,N ,N ]manganese

 imisopasem manganèse      (PBPY-7-11-2344'3')-dichloro[(4aR,13aR,17aR,21aR)-
                           1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-
                           icosahydro-11,7-nitrilo-7H-dibenzo[b,h][1,4,7,10]=
                                                         5  13   18    21   22
                           tétraazacycloheptadécine-κN ,κN ,κN ,κN ,κN ]manganèse

 imisopasem manganeso      (PBPY-7-11-2344'3')-dicloro[(4aR,13aR,17aR,21aR)-
                           1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-
                           icosahidro-7,11-(azeno)dibenzo[b,h][1,4,7,10]=
                                                     4 5   13 18  21  22
                           tetraazacicloheptadecino-κ N ,N ,N ,N ,N ]manganeso

                           C21H35Cl2MnN5

                                     H                   H
                                         N           N

                                      Cl         Mn Cl
                                     N                   N
                                 H                           H
                                                 N




 inakalantum
 inakalant                 tert-butyl (2-{7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-
                           3,7-diazabicyclo[3.3.1]nonan-3-yl}ethyl)carbamate

 inakalant                 [2-[7-[(2S)-3-(4-cyanophénoxy)-2-hydroxypropyl]-9-oxa-
                           3,7-diazabicyclo[3.3.1]non-3-yl]éthyl]carbamate de
                           1,1-diméthyléthyle

 inakalant                 (2-{7-[(2S)-3-(4-cianofenoxi)-2-hidroxipropil]-9-oxa-3,7-diazabiciclo=
                           [3.3.1]nonan-3-il}etil)carbamato de terc-butilo

                           C23H34N4O5

                           NC


                                                 O                N
                                                                      O                O H3C   CH3
                                                     H OH
                                                                             N
                                                                                   N     O      CH3
                                                                                   H

68
WHO Drug Information, Vol. 21, No. 1, 2007                                                       Recommended INN: List 57




 lapaquistatum
 lapaquistat                                 (1-{[(3R,5S)-1-(3-hydroxy-2,2-dimethylpropyl)-7-chloro-
                                             5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-
                                             3-yl]acetyl}piperidin-4-yl)acetic acid

 lapaquistat                                 acide (1-{[(3R,5S)-1-(3-hydroxy-2,2-diméthylpropyl)-7-chloro-
                                             5-(2,3-diméthoxyphényl)-2-oxo-1,2,3,5-tétrahydro-4,1-benzoxazépin-
                                             3-yl]acétyl}pipéridin-4-yl)acétique

 lapaquistat                                 ácido (1-{(3R,5S)-1-[3-hidroxi-2,2-dimetilpropil)]-7-cloro-
                                             5-(2,3-dimetoxifenil)-2-oxo-1,2,3,5-tetrahidro-4,1-benzoxazepin-
                                             3-il]acetil}piperidin-4-il)acético

                                             C31H39ClN2O8

                                                  H3C   CH3

                                              HO
                                                                    O                          CO2H
                                                            N
                                                                                    N
                                                                        H
                                             Cl                 O           O
                                                        H
                                                                    OCH3


                                                                OCH3



 levonadifloxacinum
 levonadifloxacin                            (5S)-9-fluoro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-
                                             1H,5H-benzo[ij]quinolizine-2-carboxylic acid

 lévonadifloxacine                           (-)-acide (5S)-9-fluoro-8-(4-hydroxypipéridin-1-yl)-5-méthyl-1-oxo-
                                             6,7-dihydro-1H,5H-benzo[ij]quinolizine-2-carboxylique

 levonadifloxacino                           ácido (5S)-9-fluoro-8-(4-hidroxipiperidin-1-il)-5-metil-1-oxo-
                                             6,7-dihidro-1H,5H-benzo[ij]quinolizina-2-carboxílico

                                             C19H21FN2O4

                                                                                H
                                             HO
                                                                                    CH3
                                                        N                   N


                                                        F                               CO2H
                                                                            O



 lexatumumabum*
 lexatumumab                                 immunoglobulin G1, anti-[human tumor necrosis factor receptor
                                             superfamily member 10B (TNFRSF10B, death receptor 5, TNF-
                                             related apoptosis-inducing ligand receptor 2, TRAIL-R2, CD262)]
                                             human monoclonal HGS-ETR2; gamma1 heavy chain (Homo
                                             sapiens VH-IGHG1) (224-213')-disulfide with lambda light chain
                                             (Homo sapiens V-LAMBDA- IGLC2); (230-230'':233-233'')-
                                             bisdisulfide dimer



                                                                                                                       69
Recommended INN: List 57                                             WHO Drug Information, Vol. 21, No. 1, 2007




 lexatumumab               immunoglobuline G1, anti-[membre 10B de la superfamille des
                           récepteurs du facteur de nécrose tumorale humain (TNFRSF10B,
                           death receptor 5, TRAIL-R2, CD262)] anticorps monoclonal humain
                           HGS-ETR2; chaîne lourde gamma1 (Homo sapiens VH-IGHG1)
                           (224-213')-disulfure avec la chaîne légère lambda (Homo sapiens
                           V-LAMBDA- IGLC2); dimère (230-230'':233-233'')-bisdisulfure

 lexatumumab               inmunoglobulina G1, anti-[miembro 10B de la superfamilia de
                           receptores del factor de necrosis tumoral humano (TNFRSF10B,
                           death receptor 5, TRAIL-R2, CD262)] anticuerpo monoclonal
                           humano HGS-ETR2; cadena pesada gamma1 (Homo sapiens VH-
                           IGHG1) (224-213')-disulfuro con la cadena ligera lambda (Homo
                           sapiens V-LAMBDA- IGLC2); dímero (230-230'':233-233'')-
                           bisdisulfuro

                           C6346H9832N1720O2002S42

                           Heavy chain / chaîne lourde / cadena pesada
                           EVQLVQSGGG VERPGGSLRL SCAASGFTFD                                     DYGMSWVRQA           PGKGLEWVSG   50
                           INWNGGSTGY ADSVKGRVTI SRDNAKNSLY                                     LQMNSLRAED           TAVYYCAKIL   100
                           GAGRGWYFDL WGKGTTVTVS SASTKGPSVF                                     PLAPSSKSTS           GGTAALGCLV   150
                           KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                                     SGLYSLSSVV           TVPSSSLGTQ   200
                           TYICNVNHKP SNTKVDKRVE PKSCDKTHTC                                     PPCPAPELLG           GPSVFLFPPK   250
                           PKDTLMISRT PEVTCVVVDV SHEDPEVKFN                                     WYVDGVEVHN           AKTKPREEQY   300
                           NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                                     ALPAPIEKTI           SKAKGQPREP   350
                           QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD                                     IAVEWESNGQ           PENNYKTTPP   400
                           VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                                     VMHEALHNHY           TQKSLSLSPG   450
                           K

                           Lambda chain / chaîne lambda / cadena lambda
                           SSELTQDPAV SVALGQTVRI TCQGDSLRSY                                     YASWYQQKPG           QAPVLVIYGK   50
                           NNRPSGIPDR FSGSSSGNTA SLTITGAQAE                                     DEADYYCNSR           DSSGNHVVFG   100
                           GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN                                     KATLVCLISD           FYPGAVTVAW   150
                           KADSSPVKAG VETTTPSKQS NNKYAASSYL                                     SLTPEQWKSH           RSYSCQVTHE   200
                           GSTVEKTVAP TECS

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           22-96    22'-87'      22''-96'' 22'''-87''' 136'-195' 136'''-195''' 148-204 148''-204''
                           213'-224 213'''-224'' 230-230'' 233-233'' 265-325 265''-325'' 371-429 371''-429''



 lificiguatum
 lificiguat                [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol

 lificiguat                [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]méthanol

 lificiguat                [5-(1-bencil-1H-indazol-3-il)furan-2-il]metanol

                           C19H16N2O2

                                                                O               OH
                                                   N
                                              N




 lobeglitazonum
 lobeglitazone             (5RS)-5{[4-(2-{[6-(4-methoxyphenoxy)pyrimidin-4-yl]methylamino}=
                           ethoxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione

 lobéglitazone             (5RS)-5-[4-[2-[[6-(4-méthoxyphénoxy)pyrimidin-4-yl]méthylamino]=
                           éthoxy]benzyl]thiazolidine-2,4-dione

 lobeglitazona             (5RS)-5-[4-(2-{[6-(4-metoxifenoxi)pirimidin-4-il]metilamino}etoxi)=
                           bencil]-1,3-tiazolidina-2,4-diona



70
WHO Drug Information, Vol. 21, No. 1, 2007                                                            Recommended INN: List 57


                                             C24H24N4O5S

                                             H3CO
                                                                 N        N                                      O
                                                                                            O                       and enantiomer
                                                             O                N                            S        et énantiomère
                                                                                                                 NH y enantiómero
                                                                              CH3
                                                                                                           H     O


 lorcaserinum
 lorcaserin                                  (1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine

 lorcasérine                                 (1R)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1H-3-benzazépine

 lorcaserina                                 (1R)-8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepina

                                             C11H14ClN

                                                         H CH3
                                             Cl
                                                                     NH



 mifamurtidum
 mifamurtide                                 2-[(N-{(2R)-[(2-acetamido-2,3-dideoxy-D-glucopyranos-3-yl)oxy]=
                                             propanoyl}-L-alanyl-D-isoglutaminyl-L-alanyl)amino]ethyl
                                             (2R)-2,3-bis(hexadecanoyloxy)propyl hydrogen phosphate

 mifamurtide                                 hydrogénophosphate de 2-[[N-[(2R)-2-[(3R,4R,5S,6R)-3-
                                             (acétylamino)-2,5-dihydroxy-6-(hydroxyméthyl)tétrahydro-2H-pyran-
                                             4-yloxy]propanoyl]-L-alanyl-D-isoglutaminyl-L-alanyl]amino]éthyle et
                                             de (2R)-2,3-bis(hexanoyloxy)propyle

 mifamurtida                                 hidrógenofosfato de 2-[[N-[(2R)-2-[(3R,4R,5S,6R)-3-(acetilamino)-
                                             2,5-dihidroxi-6-(hidroximetil)tetrahidro-2H-piran-4-iloxi]propanoil]-
                                             L-alanil-D-isoglutaminil-L-alanil]amino]etilo y de
                                             (2R)-2,3-bis(hexanoiloxi)propilo

                                             C59H109N6O19P

                                                                                        O
                                                         H   CH3              O     H           NH2        O
                                                                     H                                H                              O
                                             HO                      N                                N                      O
                                                                                  N                              N               P       OH
                                                                                  H                              H
                                                         O       O    H   CH3                     O    H   CH3                   O
                                                                                                                     O
                                                  O              OH                                                      H
                                             HO                                                                          O
                                                      HN         CH3                                                             O
                                                                                        CH3
                                                             O                                                       CH3     O


 migalastatum
 migalastat                                  (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol

 migalastat                                  (+)-(2R,3S,4R,5S)-2-(hydroxyméthyl)pipéridine-3,4,5-triol

 migalastat                                  (2R,3S,4R,5S)-2-(hidroximetil)piperidina-3,4,5-triol




                                                                                                                                              71
Recommended INN: List 57                               WHO Drug Information, Vol. 21, No. 1, 2007


                           C6H13NO4

                                     OH
                                 H        H
                           HO
                             H
                                          NH
                           HO
                                 H
                                          OH



 mirodenafilum
 mirodenafil               5-ethyl-2-(5-{[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl}-
                           2-propoxyphenyl)-7-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-
                           4-one

 mirodénafil               5-éthyl-2-[5-[[4-(2-hydroxyéthyl)pipérazin-1-yl]sulfonyl]-
                           2-propoxyphenyl]-7-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-
                           4-one

 mirodenafilo              5-etil-2-(5-{[4-(2-hidroxietil)piperazin-1-il]sulfonil}-2-propoxifenil)-
                           7-propil-3,5-dihidro-4H-pirrolo[3,2-d]pirimidin-4-ona

                           C26H37N5O5S

                                                                  O           CH3
                                                                        N
                                               O O          HN
                                                   S
                                               N                  N
                                          N                             CH3
                           HO                                 O                CH3



 motavizumabum*
 motavizumab               immunoglobulin G1, anti-(human respiratory syncytial virus
                           glycoprotein F) humanized monoclonal MEDI-524; gamma1 heavy
                           chain [humanized VH (Homo sapiens FR/Mus musculus CDR)-
                           Homo sapiens IGHG1] (223-213')-disulfide with kappa light chain
                           [humanized V-KAPPA (Homo sapiens FR/Mus musculus CDR)-
                           Homo sapiens IGKC]; (229-229'':232-232'')-bisdisulfide dimer

 motavizumab               immunoglobuline G1, anti-(glycoprotéine de fusion du virus syncytial
                           respiratoire humain) anticorps monoclonal humanisé MEDI-524;
                           chaîne lourde gamma1 [VH humanisé (Homo sapiens FR/Mus
                           musculus CDR)- Homo sapiens IGHG1] (223-213')-disulfure avec la
                           chaîne légère kappa [V-KAPPA humanisé (Homo sapiens FR/Mus
                           musculus CDR)-Homo sapiens IGKC]; dimère (229-229'':232-232'')-
                           bisdisulfure

 motavizumab               inmunoglobulina G1, anti-(glicoproteína de fusión del virus sincitial
                           respiratorio humano) anticuerpo monoclonal humanizado MEDI-524;
                           cadena pesada gamma1 [VH humanizada (Homo sapiens FR/Mus
                           musculus CDR)- Homo sapiens IGHG1] (223-213')-disulfuro con la
                           cadena ligera kappa [V-KAPPA humanizada (Homo sapiens FR/Mus
                           musculus CDR)- Homo sapiens IGKC]; (229-229'':232-232'')-
                           bisdisulfide dimer




72
WHO Drug Information, Vol. 21, No. 1, 2007                                                                             Recommended INN: List 57


                                             C6476H10014N1706O2008S48

                                             γ-1-Chain / Chaîne γ-1 / Cadena γ-1
                                             QVTLRESGPA LVKPTQTLTL TCTFSGFSLS                                      TAGMSVGWIR           QPPGKALEWL   50
                                             ADIWWDDKKH YNPSLKDRLT ISKDTSKNQV                                      VLKVTNMDPA           DTATYYCARD   100
                                             MIFNFYFDVW GQGTTVTVSS ASTKGPSVFP                                      LAPSSKSTSG           GTAALGCLVK   150
                                             DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                                      GLYSLSSVVT           VPSSSLGTQT   200
                                             YICNVNHKPS NTKVDKRVEP KSCDKTHTCP                                      PCPAPELLGG           PSVFLFPPKP   250
                                             KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                                      YVDGVEVHNA           KTKPREEQYN   300
                                             STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                                      LPAPIEKTIS           KAKGQPREPQ   350
                                             VYTLPPSREE MTKNQVSLTC LVKGFYPSDI                                      AVEWESNGQP           ENNYKTTPPV   400
                                             LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                                      MHEALHNHYT           QKSLSLSPGK   450


                                             κ Chain / Chaîne κ/ Cadena κ
                                             DIQMTQSPST             LSASVGDRVT              ITCSASSRVG              YMHWYQQKPG          KAPKLLIYDT   50'
                                             SKLASGVPSR             FSGSGSGTEF              TLTISSLQPD              DFATYYCFQG          SGYPFTFGGG   100'
                                             TKVEIKRTVA             APSVFIFPPS              DEQLKSGTAS              VVCLLNNFYP          REAKVQWKVD   150'
                                             NALQSGNSQE             SVTEQDSKDS              TYSLSSTLTL              SKADYEKHKV          YACEVTHQGL   200'
                                             SSPVTKSFNR             GEC                                                                                213'


                                              Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                              22-97    22''-97''    23'-87'   23'''-87''' 133'-193' 133'''-193''' 147-203 147''-203''
                                              213'-223 213'''-223'' 229-229'' 232-232'' 264-324 264''-324'' 370-428 370''-428''



 naproxcinodum
 naproxcinod                                 4-(nitrooxy)butyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate

 naproxcinod                                 (2S)-2-(6-méthoxynaphtalén-2-yl)propanoate de 4-(nitrooxy)butyle

 naproxcinod                                 (2S)-2-(6-metoxinaftalen-2-il)propanoato de 4-(nitrooxi)butilo

                                             C18H21NO6

                                                                                H     CH3
                                                                                             O                               NO2
                                                                                                                        O
                                                                                        O
                                             H3CO


 omtriptolidum
 omtriptolide                                4-{[(3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-8b-methyl-6a-(propan-
                                             2-yl)-1-oxo-1,3,3b,4,4a,6,6a,7a,7b,8b,9,10-dodecahydrotrisoxireno=
                                             [4b,5:6,7:8a,9]phenanthro[1,2-c]furan-6-yl]oxy}-4-oxobutanoic acid

 omtriptolide                                acide 4-[[(3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-8b-méthyl-
                                             6a-(1-méthyléthyl)-1-oxo-1,3,3b,4,4a,6,6a,7a,7b,8b,9,10-
                                             dodécahydrotrisoxiréno[4b,5:6,7:8a,9]phénanthro[1,2-c]furan-6-yl]=
                                             oxy]-4-oxobutanoïque

 omtriptolida                                ácido 4-{[(3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-8b-metil-
                                             6a-(propan-2-il)-1-oxo-1,3,3b,4,4a,6,6a,7a,7b,8b,9,10-
                                             dodecahidrotrisoxireno[4b,5:6,7:8a,9]fenantro[1,2-c]furan-6-il]oxi}-
                                             4-oxobutanoico

                                             C24H28O9

                                                                                             O

                                                             H
                                                        H            O           H             O

                                                     O                     CH3
                                             H3C
                                                        H   O
                                                      CH3 O                   H
                                                                                     CO2H

                                                                     O


                                                                                                                                                           73
Recommended INN: List 57                              WHO Drug Information, Vol. 21, No. 1, 2007




 pafuramidinum
 pafuramidine              4,4'-(furan-2,5-diyl)bis(N-methoxybenzenecarboximidamide)

 pafuramidine              4,4'-(furane-2,5-diyl)bis(N-méthoxybenzènecarboximidamide)

 pafuramidina              4,4'-(furano-2,5-diil)bis(N-metoxibencenocarboximidamida)

                           C20H20N4O3

                                          NH                           NH
                                  O                                             O
                           H3C        N                                     N       CH3
                                      H                                     H
                                                       O




 pramiconazolum
 pramiconazole             1-(4-{4-[4-({(2S,4R)-4-(2,4-difluorophenyl)-4-[(1H-1,2,4-triazol-
                           1-yl)methyl]-1,3-dioxolan-2-yl}methoxy)phenyl]piperazin-1-yl}phenyl)-
                           3-(propan-2-yl)imidazolidin-2-one

 pramiconazole             (+)-1-[4-[4-[4-[[(2S,4R)-4-(2,4-difluorophényl)-4-[(1H-1,2,4-triazol-
                           1-yl)méthyl]-1,3-dioxolan-2-yl]méthoxy]phényl]pipérazin-1-yl]phényl]-
                           3-(1-méthyléthyl)imidazolidin-2-one

 pramiconazol              1-(4-{4-[4-({(2S,4R)-4-(2,4-difluorofenil)-4-[(1H-1,2,4-triazol-
                           1-il)metil]-1,3-dioxolan-2-il}metoxi)fenil]piperazin-1-il}fenil)-3-(propan-
                           2-il)imidazolidin-2-ona

                           C35H39F2N7O4

                                                                                                F           F
                                                                                    H
                                                                                            O

                                            N          N        N               O       O
                           H3 C       N
                                                                                                    N
                                           O                                                            N
                                  CH3
                                                                                                N




 prinaberelum
 prinaberel                7-ethenyl-2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol

 prinabérel                7-éthényl-2-(3-fluoro-4-hydroxyphényl)-1,3-benzoxazol-5-ol

 prinaberel                7-etenil-2-(3-fluoro-4-hidroxifenil)-1,3-benzoxazol-5-ol

                           C15H10FNO3

                                          CH2
                                                       F
                                               O
                                                           OH
                           HO                  N




74
WHO Drug Information, Vol. 21, No. 1, 2007                                                                  Recommended INN: List 57


 rilonaceptum*
 rilonacept                                  [653-glycine][human interleukin-1 receptor accessory protein-
                                             (1-339)-peptide (extracellular domain fragment) fusion protein with
                                             human type 1 interleukin-1 receptor-(5-316)-peptide (extracellular
                                             domain fragment) fusion protein with human immunoglobulin G1-
                                             (229 C-terminal residues)-peptide (Fc fragment)], (659-659':662-
                                             662')-bisdisulfide dimer

 rilonacept                                  (659-659':662-662')-bisdisulfure du dimère de la
                                             [653-glycine][protéine accessoire du récepteur de l’interleukine-1
                                             humaine-(1-339)-peptide (fragment du domaine extracellulaire)
                                             protéine de fusion avec le récepteur de type I humain de
                                             l’interleukine-1-(5-316)-peptide (fragment du domaine extracellulaire)
                                             protéine de fusion avec l’immunoglobuline G1 humaine-(229 résidus
                                             C-terminaux)-peptide (fragment Fc)]

 rilonacept                                  (659-659':662-662')-bisdisulfuro del dímero de la
                                             [653-glicina][proteína accesoria del receptor de la interleukina-1
                                             humana-(1-339)-péptido (fragmento del dominio extracelular)
                                             proteína de fusión con el receptor de tipo I humano de la
                                             interleukina-1-(5-316)-péptido (fragmento del dominio extracelular)
                                             proteína de fusión con la inmunoglobulina G1 humana-(229 restos
                                             C-terminales)-péptido (fragmento Fc)]

                                             C9030H13932N2400O2670S74

                                             Monomer / Monomère / Monómero
                                             SERCDDWGLD TMRQIQVFED EPARIKCPLF                            EHFLKFNYST          AHSAGLTLIW   50
                                             YWTRQDRDLE EPINFRLPEN RISKEKDVLW                            FRPTLLNDTG          NYTCMLRNTT   100
                                             YCSKVAFPLE VVQKDSCFNS PMKLPVHKLY                            IEYGIQRITC          PNVDGYFPSS   150
                                             VKPTITWYMG CYKIQNFNNV IPEGMNLSFL                            IALISNNGNY          TCVVTYPENG   200
                                             RTFHLTRTLT VKVVGSPKNA VPPVIHSPND                            HVVYEKEPGE          ELLIPCTVYF   250
                                             SFLMDSRNEV WWTIDGKKPD DITIDVTINE                            SISHSRTEDE          TRTQILSIKK   300
                                             VTSEDLKRSY VCHARSAKGE VAKAAKVKQK                            VPAPRYTVEK          CKEREEKIIL   350
                                             VSSANEIDVR PCPLNPNEHK GTITWYKDDS                            KTPVSTEQAS          RIHQHKEKLW   400
                                             FVPAKVEDSG HYYCVVRNSS YCLRIKISAK                            FVENEPNLCY          NAQAIFKQKL   450
                                             PVAGDGGLVC PYMEFFKNEN NELPKLQWYK                            DCKPLLLDNI          HFSGVKDRLI   500
                                             VMNVAEKHRG NYTCHASYTY LGKQYPITRV                            IEFITLEENK          PTRPVIVSPA   550
                                             NETMEVDLGS QIQLICNVTG QLSDIAYWKW                            NGSVIDEDDP          VLGEDYYSVE   600
                                             NPANKRRSTL ITVLNISEIE SRFYKHPFTC                            FAKNTHGIDA          AYIQLIYPVT   650
                                             NSGDKTHTCP PCPAPELLGG PSVFLFPPKP                            KDTLMISRTP          EVTCVVVDVS   700
                                             HEDPEVKFNW YVDGVEVHNA KTKPREEQYN                            STYRVVSVLT          VLHQDWLNGK   750
                                             EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ                            VYTLPPSRDE          LTKNQVSLTC   800
                                             LVKGFYPSDI AVEWESNGQP ENNYKTTPPV                            LDSDGSFFLY          SKLTVDKSRW   850
                                             QQGNVFSCSV MHEALHNHYT QKSLSLSPGK                                                             880

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             4-102     4'-102' 27-94     27'-94' 117-161 117'-161' 140-192 140'-192' 246-312
                                             246'-312' 341-422 341'-422' 362-414 362'-414' 339-482 339'-482' 460-514 460'-514'
                                             566-630 566'-630' 659-659' 662-662' 694-754 694'-754' 800-858 800'-858'




 rosabulinum
 rosabulin                                   2-{3-[(4-cyanophenyl)methyl]indolizin-1-yl}-N-(3-methyl-1,2-thiazol-
                                             5-yl)-2-oxoacetamide

 rosabuline                                  2-[3-(4-cyanobenzyl)indolizin-1-yl]-N-(3-méthylisothiazol-5-yl)-
                                             2-oxoacétamide

 rosabulina                                  2-{3-[(4-cianofenil)metil]indolizin-1-il}-N-(3-metilisotiazol-5-il)-
                                             2-oxoacetamida




                                                                                                                                                75
Recommended INN: List 57                                   WHO Drug Information, Vol. 21, No. 1, 2007


                           C22H16N4O2S

                                                       O
                                                                 H
                                                                 N           S
                                             N                                   N
                                                            O
                                                                                 CH3
                           NC




 sagopilonum
 sagopilone                (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,12,16-tetramethyl-
                           3-(2-methyl-1,3-benzothiazol-5-yl)-10-(prop-2-enyl)-
                           4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

 sagopilone                (-)-(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,12,16-
                           tétraméthyl-3-(2-méthyl-1,3-benzothiazol-5-yl]-10-(prop-2-ényl)-
                           4,17-dioxabicyclo[14.1.0]heptadécane-5,9-dione

 sagopilona                (1S,3S,7S,10R,11S,12S,16R)-7,11-dihidroxi-8,8,12,16-tetrametil-
                           3-(2-metil-1,3-benzotiazol-5-il)-10-(prop-2-enil)-
                           4,17-dioxabiciclo[14.1.0]heptadecano-5,9-diona

                           C30H41NO6S

                                                     H3C
                                                             O
                                                                     H                  S
                                        H        H                                            CH3
                                   HO
                                             CH3                                        N
                                    H    H3C   CH3                       H
                                                                     O
                           H2C
                                                 H
                                             O       OH      O



 sodelglitazarum
 sodelglitazar             2-{4-[({2-[2-fluoro-4-(trifluromethyl)phenyl]-4-methyl-1,3-thiazol-
                           5-yl}methyl)sulfanyl]-2-methylphenoxy}-2-methylpropanoic acid

 sodelglitazar             acide 2-[4-[[[2-[2-fluoro-4-(trifluorométhyl)phényl]-4-méthyl-
                           1,3-thiazol-5-yl]méthyl]sulfanyl]-2-méthylphénoxy]-
                           2-méthylpropanoïque

 sodelglitazar             ácido 2-{4-[({2-[2-fluoro-4-(trifluorometil)fenil]-4-metil-1,3-tiazol-
                           5-il}metil)sulfanil]-2-metilfenoxi}-2-metilpropanoico

                           C23H21F4NO3S2

                                                 N        CH3
                           F3C
                                                             S
                                                 S
                                                                                 H3 C   CH3
                                         F
                                                                                  O         CO2H
                                                                         CH3




76
WHO Drug Information, Vol. 21, No. 1, 2007                                                               Recommended INN: List 57


 sofigatranum
 sofigatran                                  propyl {(1S)-1-{(2S)-2-[(trans-4-aminocyclohexylmethyl)carbamoyl]=
                                             pyrrolidine-1-carbonyl}-2-methyl-2-[(propan-2-yl)sulfanyl]propyl}=
                                             carbamate

 sofigatran                                  [(1S)-1-[[(2S)-2-[[(trans-4-aminocyclohexyl)méthyl]carbamoyl]=
                                             pyrrolidin-1-yl]carbonyl]-2-méthyl-2-[(1-méthyléthyl)sulfanyl]propyl]=
                                             carbamate de propyle

 sofigatrán                                  [(1S)-1-[[(2S)-2-[[(trans-4-aminociclohexil)metil]carbamoil]pyrrolidin-
                                             1-il]carbonil]-2-metil-2-[(propan-2-il)sulfanil]propil]carbamato de
                                             propilo

                                             C24H44N4O4S

                                                                                        H3C
                                             H2N                                                   CH3
                                                                                         S
                                                                    H                             CH3
                                                                    N             N
                                                                                                  CH3
                                                                             H
                                                                        O                     H
                                                                                  O     HN         O
                                                                                                            CH3
                                                                                              O



 succinobucolum
 succinobucol                                4-{4-[(2-{[3,5-di(tert-butyl)-4-hydroxyphenyl]sulfanyl}propan-2-yl)=
                                             sulfanyl]-2,6-di(tert-butyl)phenoxy}-4-oxobutanoic acid

 succinobucol                                acide 4-[4-[[1-[[3,5-bis(1,1-diméthyléthyl)-4-hydroxyphényl]sulfanyl]-
                                             1-méthyléthyl]sulfanyl]-2,6-bis(1,1-diméthyléthyl)phénoxy]-
                                             4-oxobutanoïque

 succinobucol                                ácido 4-{4-[(2-{[3,5-di(terc-butil)4-hidroxifenil]sulfanil}propan-2-il)=
                                             sulfanil]-2,6-di(terc-butil)fenoxi}-4-oxobutanoico

                                             C35H52O5S2

                                                              CH3                H3 C
                                                     H3 C                                 CH3      O
                                                               CH3           H3 C
                                                   HO                                          O            CO2H
                                                                H3C         CH3
                                             H3C                                                   CH3
                                                                    S        S
                                               H3C      CH3                              H3C       CH3



 taribavirinum
 taribavirin                                 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboximidamide

 taribavirine                                1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboximidamide

 taribavirina                                1-β-D-ribofuranosil-1H-1,2,4-triazol-3-carboximidamida




                                                                                                                               77
Recommended INN: List 57                                             WHO Drug Information, Vol. 21, No. 1, 2007


                           C8H13N5O4

                                         NH2

                                    HN               N
                           HO                N
                                         O       N




                                    OH       OH



 tezampanelum
 tezampanel                (3S,4aR,6R,8aR)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-
                           3-carboxylic acid

 tézampanel                (-)-acide (3S,4aR,6R,8aR)-6-[2-(1H-tétrazol-5-yl)éthyl]=
                           décahydroisoquinoléine-3-carboxylique

 tezampanel                (-)-ácido (3S,4aR,6R,8aR)-6-[2-(1H-tetrazol-5-il)etil]=
                           decahidroisoquinolina-3-carboxílico

                           C13H21N5O2

                                                         H
                                N
                           N
                                                                     NH
                           N
                                N                                         H
                                H
                                             H           H               CO2H




 ticagrelorum
 ticagrelor                (1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]=
                           amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-
                           5-(2-hydroxyethoxy)cyclopentane-1,2-diol

 ticagrélor                (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophényl)cyclopropyl]=
                           amino]-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-
                           5-(2-hydroxyéthoxy)cyclopentane-1,2-diol

 ticagrelor                (1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-difluorofenil)ciclopropil]amino}-
                           5-(propilsulfanil)-3H-[1,2,3]triazolo[4,5-d]pirimidin-3-il)-
                           5-(2-hidroxietoxi)ciclopentano-1,2-diol

                           C23H28F2N6O4S

                                         H3C                                          F       F
                                                             S
                                                                         N
                                               OH OH N                           NH
                                             H      H                        H            H
                                         O                       N       N
                           HO                                        N
                                         H                   H




78
WHO Drug Information, Vol. 21, No. 1, 2007                                                          Recommended INN: List 57


 tigapotidum
 tigapotide                                  L-glutamyl-L-tryptophyl-L-glutaminyl-L-threonyl-L-aspartyl-
                                             L-asparaginyl-S-[(acetamido)methyl]-L-cysteinyl-L-glutamyl-
                                             L-threonyl-S-[(acetamido)methyl]-L-cysteinyl-L-threonyl-
                                             S-[(acetamido)methyl]-L-cysteinyl-L-tyrosyl-L-glutamyl-L-threonine
                                              37    40   42
 tigapotide                                  S -S ,S -tris[(acétylamino)méthyl]bêta-microséminoprotéine
                                             humaine (protéine PSP94 sécrétée par la prostate)-(31-45)-peptide
                                              37    40   42
 tigapotida                                  S -S ,S -tris[(aceltilamino)metil]beta-microseminoproteína humana
                                             (proteína PSP94 secretada por la próstata)-(31-45)-péptido

                                             C82H119N21O34S3

                                                                       O            CH3   O            CH3        O        CH3

                                                                           HN                 HN                      NH
                                                                                S                  S          S
                                             H Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr OH




 tipelukastum
 tipelukast                                  4-(6-acetyl-3-{3-[(4-acetyl-3-hydroxy-2-propylphenyl)sulfanyl]=
                                             propoxy}-2-propylphenoxy)butanoic acid

 tipélukast                                  acide 4-[6-acétyl-3-[3-[(4-acétyl-3-hydroxy-2-propylphényl)sulfanyl]=
                                             propoxy]-2-propylphénoxy]butanoïque

 tipelukast                                  ácido 4-[6-acetil-3-[3-[(4-acetil-3-hidroxi-2-propilfenil)sulfanil]=
                                             propoxi]-2-propilfenoxi]butanoico

                                             C29H38O7S

                                                    O                                              O

                                             H3 C                                                       CH3

                                                    HO          S               O                  O                  CO2H



                                                              CH3                             CH3




 tomopenemum
 tomopenem                                   (4R,5S,6S)-3-({(3S,5S)-5-[(3S)-3-(carbamimidamidoacetamido)=
                                             pyrrolidine-1-carbonyl]-1-methylpyrrolidin-3-yl}sulfanyl)-
                                             6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-
                                             2-ene-2-carboxylic acid

 tomopénem                                   (-)-acide (4R,5S,6S)-3-[[(3S,5S)-5-[[(3S)-3-[[(carbamimidoylamino)=
                                             acétyl]amino]pyrrolidin-1-yl]carbonyl]-1-méthylpyrrolidin-3-yl]=
                                             sulfanyl]-6-[(1R)-1-hydroxyéthyl]-4-méthyl-7-oxo-1-azabicyclo[3.2.0]=
                                             hept-2-ène-2-carboxylique

 tomopenem                                   ácido (4R,5S,6S)-3-{[(3S,5S)-5-({(3S)-3-
                                             (carbamimidamidoacetamido)pirrolidin-1-il}carbonil)-1-metilpirrolidin-
                                             3-il]sulfanil}-6-[(1R)-1-hidroxietil]-4-metil-7-oxo-1-azabiciclo[3.2.0]=
                                             hept-2-eno-2-carboxílico




                                                                                                                                 79
Recommended INN: List 57                                    WHO Drug Information, Vol. 21, No. 1, 2007


                           C23H35N7O6S

                                                CO2H
                                  O
                            H3C           N
                                                    S                 O
                                                                                                          NH
                           HO                     H                                       H
                                  H   H   H H    CH3                      N               N
                                                                  H                                   N        NH2
                                                            N                             H           H
                                                                CH3                           O




 tylvalosinum
 tylvalosin                (4R,5S,6S,7R,9R,11E,13E,15R,16R)-15-{[(6-deoxy-2,3-di-O-methyl-
                           β-D-allopyranosyl)oxy]methyl}-6-({3,6-dideoxy-4-O-[2,6-dideoxy-
                           3-C-methyl-4-O-(3-methylbutanoyl)-α-L-ribo-hexopyranosyl]-
                           3-(dimethylamino)-β-D-glucopyranosyl}oxy)-16-ethyl-5,9,13-trimethyl-
                           2,10-dioxo-7-(2-oxoethyl)oxacyclohexadeca-11,13-dien-4-yl acetate

 tylvalosine               (-)-acétate de (4R,5S,6S,7R,9R,11E,13E,15R,16R)-15-[[(6-désoxy-
                           2,3-di-O-méthyl-β-D-allopyranosyl)oxy]méthyl]-6-[[3,6-didésoxy-
                           4-O-[2,6-didésoxy-3-C-méthyl-4-O-(3-méthylbutanoyl)-α-L-ribo-
                           hexopyranosyl]-3-(diméthylamino)-β-D-glucopyranosyl]oxy]-16-éthyl-
                           5,9,13-triméthyl-2,10-dioxo-7-(2-oxoéthyl)oxacyclohexadéca-
                           11,13-dién-4-yle

 tilvalosina               (-)-acetato de (4R,5S,6S,7R,9R,11E,13E,15R,16R)-15-[[(6-desoxi-
                           2,3-di-O-metil-β-D-alopiranosil)oxi]metil]-6-[[3,6-didesoxi-
                           4-O-[2,6-didesoxi-3-C-metil-4-O-(3-metilbutanoil)-α-L-ribo-
                           hexopiranosil]-3-(dimetilamino)-β-D-glucopiranosil]oxi]-16-etil-
                           5,9,13-trimetil-2,10-dioxo-7-(2-oxoetil)oxaciclohexadeca-11,13-dien-
                           4-ilo

                           C53H87NO19

                                                                                          O
                                                                               H3C
                                                                               H
                                                                  OHC
                                                                                                      CH3
                                  CH3                       CH3           H
                                                                                          CH3         H
                                                                   O O
                           H3C                      H3C          CH3                       H O
                                                            N                 H
                                                    O                                                      H CH3         O
                                  O       O             O                         O               O
                                                                                      H                              O
                                              CH3
                                              OH                      OH                          H3C
                                                                           O          CH3
                                                                                                          HO
                                              CH3                                                         H3CO       OCH3



 vabicaserinum
 vabicaserin               (9aR*,12aS*)-4,5,6,7,9,9a,10,11,12,12a-
                           decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline

 vabicasérine              (-)-(9aR*,12aS*)-4,5,6,7,9,9a,10,11,12,12a-
                           décahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoléine

 vabicaserina              (-)-(9aR*,12aS*)-4,5,6,7,9,9a,10,11,12,12a-
                           decahidrociclopenta[c][1,4]diazepino[6,7,1-ij]quinolina




80
WHO Drug Information, Vol. 21, No. 1, 2007                                                    Recommended INN: List 57


                                             C15H20N2


                                                   H
                                                                          or enantiomer, (-)-isomer
                                                                          ou énantiomère, (-)-isomère
                                                                     NH   o enantiómero, (-)-isómero
                                                            N
                                                   H



 vapitadinum
 vapitadine                                  5,6-dihydrospiro(imidazo[2,1-b][3]benzazepine-11,4'-piperidine)-
                                             3-carboxamide

 vapitadine                                  5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazépine-11,4'-pipéridine]-
                                             3-carboxamide

 vapitadina                                  5,6-dihidrospiro(11H-imidazo[2,1-b][3]benzazepina-11,4'-piperidina)-
                                             3-carboxamida

                                             C17H20N4O


                                                                NH



                                                    N       N


                                             H2N
                                                       O



 veliflaponum
 veliflapon                                  (2R)-cyclopentyl{4-[(quinolin-2-yl)methoxy]phenyl}acetic acid

 véliflapon                                  (+)-acide (2R)-cyclopentyl[4-(quinoléin-2-ylméthoxy)phényl]acétique

 veliflapón                                  (+)-ácido (2R)-ciclopentil[4-(quinolin-2-ilmetoxi)fenil]acético

                                             C23H23NO3

                                                                              H   CO2H



                                                        N
                                                                     O




 volinanserinum
 volinanserin                                (R)-(2,3-dimethoxyphenyl){1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}=
                                             methanol

 volinansérine                               (+)-(R)-(2,3-diméthoxyphényl)[1-[2-(4-fluorophényl)éthyl]pipéridin-
                                             4-yl]méthanol

 volinanserina                               (+)-(R)-(2,3-dimetoxifenil)[1-[2-(4-fluorofenil)etil]piperidin-4-il]metanol




                                                                                                                       81
Recommended INN: List 57                                                  WHO Drug Information, Vol. 21, No. 1, 2007


                                                 C22H28FNO3

                                                  F
                                                                                   OCH3
                                                                         H3CO
                                                                   N



                                                                           H OH




                              AMENDMENTS TO PREVIOUS LISTS
                      MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                          MODIFICACIONES A LAS LISTAS ANTERIORES



Recommended International Non Proprietary Names (Rec. INN): List 53
Dénominations communes internationales recommandées (DCI Rec.): Liste 53
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 53
(WHO Drug Information, Vol. 19, No. 1, 2005)

p. 80   delete/supprimer/suprímase   insert/insérer/insertése
        gantacurium chloridum        gantacurii chloridum

p. 88   panitumumabun
        panitumumab                  replace the molecular formula by the following
        panitumumab                  remplacer la formule brute par la suivante
        panitumumab                  sustitúyase la fórmula molecular por la siguiente

                                     C6398H9878N1694O2016S48

p. 88   pelitinibum
        pelitinib                     sustitúyase el nombre químico por el siguiente:
                                      (2E)-N-[3-ciano-4-[(3-cloro-4-fluorofenil)amino]-7-etoxiquinolin-6-il]-
                                      4-(dimetilamino)-2-butenamina



Recommended International Non Proprietary Names (Rec. INN): List 55
Dénominations communes internationales recommandées (DCI Rec.): Liste 55
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 55
(WHO Drug Information, Vol. 20, No. 1, 2006)

p. 45   suprimáse                    insértese
        nebicapone                   nebicapona




* Electronic structure available on Mednet: http://mednet.who.int/
* Structure électronique disponible sur Mednet: http://mednet.who.int/
* Estructura electrónica disponible en Mednet: http://mednet.who.int/

82
    WHO Drug Information, Vol. 21, No. 1, 2007                                               Recommended INN: List 57




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




                                                                                                                     83
